-
Product Insights
New![]()
Net Present Value Model: Gritstone Bio Inc’s SLATE-001
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Gritstone Bio Inc’s GRANITE-001
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Non-Small Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Non-Small Cell Lung Cancer Drug Details: SLATE-001 is under development for the treatment...
-
Company Profile
![]()
Gritstone Bio Inc – Company Profile
Gritstone Bio Inc (Gritstone Bio) carries out the discovery, development, manufacture and deliver of the cancer and infectious disease immunotherapy candidates. The company product candidate comprises GRT-R910 (samRNA), GRT-C907(ChAd)/-R908 (samRNA), GRT- C909 (ChAd)/- R910(samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA). Its infectious diseases pipeline includes coral, a second-generation COVID-19 vaccine program and HIV therapeutic vaccine candidate. Gritstone Bio’s oncology programs comprise granite, an individualized neoantigen-based immunotherapy and slate, to treat non-small cell lung cancer. It also provides Gritstone edge...
Add to Basket -
Product Insights
New![]()
Net Present Value Model: Harpoon Therapeutics Inc’s HPN-536
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Pancreatic Ductal Adenocarcinoma Drug Details: SLATE-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Metastatic Colorectal Cancer Drug Details: SLATE-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SLATE-001 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SLATE-001 in Solid Tumor Drug Details: SLATE-001 is under development for the treatment of KRAS...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Danvilostomig in Oral Cavity (Mouth) Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Danvilostomig in Oral Cavity (Mouth) Cancer Drug Details: Danvilostomig (SIB-003) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Anti-inflammatory in Post-Operative Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Anti-Inflammatory in Post-Operative Pain Drug Details:Drugs are under development for the treatment of inflammation and pain post...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Simufilam Hydrochloride in Dementia Associated With Alzheimer’s Disease
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Simufilam Hydrochloride in Dementia Associated With Alzheimer's Disease Drug Details: Simufilam (formerly known as sumifilam)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Human Immuno Deficiency Virus Vaccine in Human Immunodeficiency Virus (HIV) Infections (AIDS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Human Immuno Deficiency Virus Vaccine in Human Immunodeficiency Virus (HIV) Infections (AIDS) Drug Details: Vaccine candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – MRNA-1012 in Influenza A Virus, H1N1 Subtype Infections
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.MRNA-1012 in Influenza A Virus, H1N1 Subtype InfectionsDrug Details: mRNA-1012 is under development for the prevention...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – FB-610 in Parkinson’s Disease
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. FB-101 in Parkinson's Disease Drug Details: FB-610 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CID-103 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CID-103 in Relapsed Multiple Myeloma Drug Details:CID-103 (TSK-011010) is under development for the treatment of relapsed...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ABBV-383 in Relapsed Multiple Myeloma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.ABBV-383 in Relapsed Multiple Myeloma Drug Details:TNB-383B is under development for the treatment of relapsed and...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – CT-041 in Adenocarcinoma Of The Gastroesophageal Junction
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.CT-041 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: CT-041 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GRANITE-001 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GRANITE-001 in Non-Small Cell Lung CancerDrug Details: GRANITE-001 (Zvexneo) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GRANITE-001 in Pancreatic Ductal Adenocarcinoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GRANITE-001 in Pancreatic Ductal AdenocarcinomaDrug Details: GRANITE-001 (Zvexneo) is under development for the treatment of pancreatic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – GRANITE-001 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.GRANITE-001 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)Drug Details: GRANITE-001 (Zvexneo) is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.